Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

A new study published in Nanotechnology offers new hope for less harmful breast cancer therapy by combining two powerful, non ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

Herceptin has benefited about three million people since that time, dramatically increasing the 10-year survival rate—and the cancer-free rate—for what was once one of the worst medical diagnoses.

DelveInsight’s Breast Cancer pipeline report depicts a robust space with 100+ Breast Cancer companies working to develop 120+ pipeline therapies for Breast Cancer treatment.

Jazz Pharmaceuticals (($JAZZ)) announced an update on their ongoing clinical study. The clinical study titled A Phase 3, Randomized, Open-label, ...

LUND, SWEDEN / ACCESS Newswire / July 14, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that it has dosed the first patient ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

PURPOSEGEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment ...